… of clinical use of three EGFR TKIs (afatinib, gefitinib, and erlotinib). We found that gefitinib
was more commonly used than erlotinib or afatinib in Korea, especially for elderly, which may …

… We believe that the accumulated evidence with erlotinib and gefitinib indicates gefitinib's
activity and safety as a cancer therapeutic for patients with NSCLC is at least as good as that of …

… gefitinib and erlotinib are effective for advanced non-small cell lung cancer (NSCLC). This
meta-analysis compared their effectiveness and safety… antitumor effectiveness and safety of …

… anti-tumor efficacy of gefitinib and erlotinib. However, our results indirectly prove that both
gefitinib and erlotinib are more … Both median PFS (gefitinib group, 11.4 months vs. 4.9 months; …

… No solid evidence was found that afatinib had greater efficacy than gefitinib or erlotinib in …
, or safety.8, 19 To our knowledge, that was the only randomized trial with direct comparison of …

… To evaluate the efficacy and safety of erlotinib for non-small cell lung … (8,9), as is gefitinib, it
is also suggested to be effective in … However, studies investigating their efficacy and safety in …

… gefitinib (61.7%) than with erlotinib (17.8%) or afatinib (20.1%) (p < 0.01). A risk-benefit
contour was used to assess the trade-off between efficacy … with both erlotinib and gefitinib. With …

… gefitinib and icotinib (P<0.05). In conclusion, gefitinib, erlotinib and icotinib had similar
effectiveness … However, gefitinib resulted in a lower frequency of fatigue, and nausea and vomiting…

… conducted to compare the safety and efficacy of erlotinib with that of gefitinib in advanced
non… We aimed to determine whether erlotinib is superior to gefitinib in efficacy. The primary end …

… Gefitinib and erlotinib are potent EGFR TKIs, with antitumor activity. In this randomized,
single-center, non-comparative phase II trial, the efficacy and safety of gefitinib and erlotinib was …